The immunohistochemical analysis indicated that the fibroblasts were targeted at low-dose-cisplatin since their nuclei became fragmented and they lost the Ki67 staining (Figure 6B, row 3), whereas no obvious effect was seen in the cancer cells. Here, MKI67 is linked to cancer.